

Taxus Cardium Pharmaceuticals Group Inc (CRXM) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/T77DF056A70EN.html>

Date: August 2017

Pages: 34

Price: US\$ 125.00 (Single User License)

ID: T77DF056A70EN

Abstracts

Taxus Cardium Pharmaceuticals Group Inc (CRXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities – A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Taxus Cardium Pharmaceuticals Group Inc (Cardium) is a development stage company with focus on regenerative medicine. It develops manufacturing process and technology platforms for cardiovascular disease, wound healing and tissue engineering based on its core gene therapy. Its product portfolio includes FDA approved Excellagen topical gel, a cellular biological skin substitute used for wound care management; and Generx, an interventional cardiology, angiogenic gene therapy product candidate used for the treatment of cardiac microvascular insufficiency. The company also holds non-core interests in the Cell-nique d/b/a Healthy Brands Collective, a health products company, and LifeAgain Insurance Solutions, Inc., an advanced medical data analytics business. Cardium markets its products through third party commercialization partners. The company is headquartered in San Diego, California, the US.

Taxus Cardium Pharmaceuticals Group Inc Key Recent Developments

Dec 14,2016: Taxus Cardium Announces Two Director Retirements Following A

Decade Of Distinguished Service

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Taxus Cardium Pharmaceuticals Group Inc - Key Facts
Taxus Cardium Pharmaceuticals Group Inc - Key Employees
Taxus Cardium Pharmaceuticals Group Inc - Key Employee Biographies
Taxus Cardium Pharmaceuticals Group Inc - Major Products and Services
Taxus Cardium Pharmaceuticals Group Inc - History
Taxus Cardium Pharmaceuticals Group Inc - Company Statement
Taxus Cardium Pharmaceuticals Group Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Taxus Cardium Pharmaceuticals Group Inc - Business Description
Taxus Cardium Pharmaceuticals Group Inc - Corporate Strategy
Taxus Cardium Pharmaceuticals Group Inc - SWOT Analysis
SWOT Analysis - Overview
Taxus Cardium Pharmaceuticals Group Inc - Strengths
Taxus Cardium Pharmaceuticals Group Inc - Weaknesses
Taxus Cardium Pharmaceuticals Group Inc - Opportunities
Taxus Cardium Pharmaceuticals Group Inc - Threats
Taxus Cardium Pharmaceuticals Group Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Taxus Cardium Pharmaceuticals Group Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017
Taxus Cardium Pharmaceuticals Group Inc, Medical Equipment, Deals By Type, 2011

to YTD 2017

Taxus Cardium Pharmaceuticals Group Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Dec 14, 2016: Taxus Cardium Announces Two Director Retirements Following A Decade Of Distinguished Service

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Taxus Cardium Pharmaceuticals Group Inc, Key Facts
Taxus Cardium Pharmaceuticals Group Inc, Key Employees
Taxus Cardium Pharmaceuticals Group Inc, Key Employee Biographies
Taxus Cardium Pharmaceuticals Group Inc, Major Products and Services
Taxus Cardium Pharmaceuticals Group Inc, History
Taxus Cardium Pharmaceuticals Group Inc, Subsidiaries
Taxus Cardium Pharmaceuticals Group Inc, Key Competitors
Taxus Cardium Pharmaceuticals Group Inc, Ratios based on current share price
Taxus Cardium Pharmaceuticals Group Inc, Annual Ratios
Taxus Cardium Pharmaceuticals Group Inc, Annual Ratios (Cont.1)
Taxus Cardium Pharmaceuticals Group Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017
Taxus Cardium Pharmaceuticals Group Inc, Medical Equipment, Deals By Type, 2011 to YTD 2017
Taxus Cardium Pharmaceuticals Group Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Taxus Cardium Pharmaceuticals Group Inc, Performance Chart (2011 - 2015)

Taxus Cardium Pharmaceuticals Group Inc, Ratio Charts

Taxus Cardium Pharmaceuticals Group Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017

Taxus Cardium Pharmaceuticals Group Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Organogenesis Inc

MiMedx Group Inc

Juventas Therapeutics Inc

Collagen Solutions Plc

CardioVascular BioTherapeutics Inc

3-D Matrix, Inc.

I would like to order

Product name: Taxus Cardium Pharmaceuticals Group Inc (CRXM) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/T77DF056A70EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T77DF056A70EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

